Abstract: In these metal oxide microparticles, surfaces of microparticles of a metal oxide are modified by a fatty acid having 5 or more and 14 or less carbon atoms and having a branched chain, the metal oxide is metal oxides of a plurality of kinds of metals selected from the group consisting of Zn, In, Sn, and Sb, and an average particle diameter of the microparticles is 80 nm or less. In a dispersion for forming an infrared-shielding film, the metal oxide microparticles are dispersed in a hydrophobic solvent, and a light transmittance in a wavelength range of 800 nm to 1,100 nm is 20% or more and less than 70%.

Abstract: A quantum dot stabilized by a halogen salt includes a compound of Group 13 and Group 15, a compound of Group 12 and Group 16 or a compound of Group 14 and Group 16. The quantum dot has a crystalline structure and at least a portion of a surface of the quantum dot is combined with a halogen salt. Thus, the quantum dot has a high stability in an air.

Abstract: The present invention relates to a liquid indium alkoxide-containing composition comprising at least one indium alkoxide and at least three solvents L1, L2 and L3, in which the solvent L1 is selected from the group consisting of ethyl lactate, anisole, tetrahydrofurfuryl alcohol, butyl acetate, ethylene glycol diacetate and ethyl benzoate, and the difference between the boiling points of the two solvents L2 and L3 under SATP conditions is at least 30° C., to processes for preparation thereof and to the use thereof.

Abstract: The invention relates to a dental restorative material which comprises a thermolabile or photolabile polymerizable compound of Formula I: [(Z1)m-Q1-X)]k-T-[Y-Q2-(Z2)n]1??Formula I, in which T represents a thermolabile or photolabile group, Z1 and Z2 in each case independently represent a polymerizable group selected from vinyl groups, CH2?CR1—CO—O— and CH2?CR1—CO—NR2— or an adhesive group selected from —Si(OR)3, —COOH, —O—PO(OH)2, —PO(OH)2, —SO2OH and —SH, wherein at least one Z1 or Z2 is a polymerizable group, Q1 in each case independently is missing or represents an (m+1)-valent linear or branched aliphatic C1-C20 radical which can be interrupted by —O—, —S—, —CO—O—, —O—CO—, —CO—NR3—, —NR3—CO—, —O—CO—NR3—, —NR3—CO—O— or —NR3—CO—NR3—, Q2 in each case independently is missing or represents an (n+1)-valent linear or branched aliphatic C1-C20 radical which can be interrupted by —O—, —S—, —CO—O—, —O—CO—, —CO—NR3—, —NR3—CO—, —O—CO—NR3—, —NR3—CO—O— or —NR3—CO—NR3—, X and Y in each case independently are missing

Abstract: It is an object of the present invention to provide a mixture for recovery utilization or transfer of carbon dioxide gas. According to the present invention, disclosed is a mixture containing carbon dioxide and an alkyltin alkoxide composition containing carbon dioxide complex of an alkyltin alkoxide, the mixture having a composition with a specified ratio.

Abstract: The invention is drawn to a composition comprising a tin(II) 2-hydroxycarboxylate, where the 2-hydroxycarboxylate is preferably selected from the group consisting of glycolate, lactate, mandelate and 2-hydroxybutyrate. The tin(II) 2-hydroxycarboxylates may be prepared by a method comprising the steps of (a) providing an aqueous solution of a tin(II) salt, (b) adding a 2-hydroxycarboxylic acid, or a salt of a 2-hydroxycarboxylic acid, (c) further adding a base, wherein the tin(II) 2-hydroxycarboxylate precipitates, (d) optionally, isolating the tin(II) 2-hydroxycarboxylate, and (e) optionally, drying. The tin(II) 2-hydroxycarboxylates and compositions containing them are useful in oral care applications, and as catalysts for chemical condensation reactions and/or the production of polymers.

Abstract: Methods for precise and predictable modification of previously synthesized nanocrystals. The methods rely on the solubility behavior of crystalline materials to provide for controlled reversal of the nanocrystal growth process (i.e., dissolution). A method for post-synthesis modification of colloidal nanocrystals includes (1) providing a first nanocrystal having a first size and a first shape, (2) forming a reaction mixture that includes the nanocrystal, at least one ligand capable of binding to at least one component of the nanocrystal, at least one solvent, and an inert gas atmosphere, and (3) modifying the size and/or shape of the nanocrystal in the reaction mixture for a period of time at a temperature in a range from about 100 0C to about 240 0C so as to produce at least a second nanocrystal having a second size and/or a second shape.

Abstract: The invention relates to a composite material comprising nanoparticles of at least one metal derivative and at least one type of carboxylic and/or sulfonic acid derivative organic compound chemically bound in a covalent manner with said nanoparticles by means of at least one carboxylic and/or sulfonic function.

Abstract: An economic, direct synthetic method for producing water soluble QDs that are ready for bioconjugation is provided. The method can produce aqueous QDs with emission wavelengths varying from 400 nm to 700 nm Highly luminescent metal sulfide (MS) QDs are produced via an aqueous synthesis route. MS QDs are capped with thiol-containing charged molecules in a single step. The resultant MS QDs exhibit the distinctive excitonic photoluminescence desired of QDs and can be fabricated to avoid undesirable broadband emissions at higher wavelengths. This provides a significant improvement over the present complex and expensive commercial processes for the production of QDs. The aqueous QDs are stable in biological fluids over a long period of time. In addition, nontoxic ZnS QDs have been produced with good photoluminescence properties by refluxing the ZnS QD suspensions over a period of time.

Abstract: To provide ?-substituted vinyltin useful for the search for function-developing substances such as pharmaceuticals/agrichemicals and functional materials and for the construction of a compound library. An ?-substituted vinyltin compound represented by the formula (1), a tautomer or salt of the compound or a solvate thereof: R2CH?C(R3)Sn(R1)3??(1) wherein R1 is a C1-10 alkyl group, a C2-14 aryl group or the like, R2 is a C2-14 aryl group, a C2-9 heterocyclyl group, a C3-10 cycloalkyl group or the like, and R3 is a carbamoyl group, a thiocarbamoyl group, an isocyanate group, an isothiocyanate group, a formylamino group, a thioformylamino group, an isonitrile group, an urea group, a carbamate group or the like.

Abstract: A dietary source of mineral in the form of a metal carboxylate is prepared using the acid-base-like reaction. A salt of a carboxylate anion and a by-product cation is reacted in aqueous solution with a salt of a metal cation and a by-product anion under conditions which form a metal carboxylate and the by-product salt. Solutions formed in the reaction may be applied directly to a dry carrier to produce a dry dietary supplement or, alternatively, the solutions may be filtered to remove precipitated by-product salt and the filtrate used as a liquid dietary supplement. Preferably, a reducing agent, such as ascorbic acid, is added to help prevent the oxidation of divalent to trivalent form of a metal salt, when an easily oxidized divalent metal is used as starting material.

Abstract: Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.

Abstract: The present invention provides a low melting point tin salt of aliphatic monocarboxylic acid obtained by a process comprising, reacting an aliphatic monocarboxylic acid having 4 to 30 carbon atoms or its salt and an inorganic tin compound so as to prepare a tin salt of aliphatic monocarboxylic acid, and bringing the tin salt in contact with an oxygen supplying substance.

Abstract: The synthesis, processing and test of improved lead zirconate titanate (PZT) precursor materials useful for making bulk, thick films and thin films of PZT are provided. PZT is an oxide ceramic extensively used for its piezoelectric properties. A variety of devices made from piezoelectric PZT are known. A soluble spin-on precursor is provided that is compatible with and soluble in non-toxic and environmentally benign solvents (including water), has high stability and long shelf life, and provides high quality PZT films.

Abstract: A multi-functional photoinitiator of formula (I) R1m—Q—(A1—PI)n??(I) wherein Q is a heteroatom selected from Si, Ti, Zr and Sn or any two independently selected such heteroatoms linked by a covalent bond or a by C1-16 (preferably C1-9) alkylene group, n is at least 2 and n+m=the functionality of Q, each R1 is the same or different and is a non-photoinitiator group; each group PI is the same or different and is a photoinitiator group. Each —A1— is the same or different and is selected from linking groups of formula —(A2)p—Z— wherein p has an average of from 1 to 10, preferably from 3 to 5 and the groups —A2— are either (a) each independently selected from C2-4 alkyleneoxy groups; or (b) each independently selected from groups of formula —O—(CH2)qCO— wherein q is from 3 to 5, and Z is selected from —O—, —S— and —NR6— where R6 is C1-6 alkyl.

Abstract: The present invention provides a low melting point tin salt of aliphatic monocarboxylic acid obtained by a process comprising, reacting an aliphatic monocarboxylic acid having 4 to 30 carbon atoms or its salt and an inorganic tin compound so as to prepare a tin salt of aliphatic monocarboxylic acid, and bringing the tin salt in contact with an oxygen supplying substance.

Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such resins may be used in dental restorative materials to help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.

Abstract: A liquid precursor for forming a transparent metal oxide thin film comprises a first organic precursor compound. In one embodiment, the liquid precursor is for making a conductive thin film. In this embodiment, the liquid precursor contains a first metal from the group including tin, antimony, and indium dissolved in an organic solvent. The liquid precursor preferably comprises a second organic precursor compound containing a second metal from the same group. Also, the liquid precursor preferably comprises an organic dopant precursor compound containing a metal selected from the group including niobium, tantalum, bismuth, cerium, yttrium, titanium, zirconium, hafnium, silicon, aluminum, zinc and magnesium. Liquid precursors containing a plurality of metals have a longer shelf life. The addition of an organic dopant precursor compound containing a metal, such as niobium, tantalum or bismuth, to the liquid precursor enhances control of the conductivity of the resulting transparent conductor.

Abstract: Novel methods are provided for the manufacture of 117mSn(Sn4+) DTPA. The method allows the use of DTPA, a toxic chelating agent, in an approximately 1:1 ratio to 117mSn(Sn4+) via either aqueous conditions, or using various organic solvents, such as methylene chloride. A pharmaceutical composition manufactured by the novel method is also provided, as well as methods for treatment of bone tumors and pain associated with bone cancer using the pharmaceutical composition of the invention.

Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) useful for oral testosterone replacement therapy. Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds bind reversibly to the androgen receptor.

Abstract: Novel ligated compounds of tin, titanium, and zinc are useful as metal oxide CVD precursor compounds without the detriments of extreme reactivity yet maintaining the ability to produce high quality metal oxide coating by contact with heated substrates.

Abstract: A liquid precursor for forming a transparent metal oxide thin film comprises a first organic precursor compound. In one embodiment, the liquid precursor is for making a conductive thin film. In this embodiment, the liquid precursor contains a first metal from the group including tin, antimony, and indium dissolved in an organic solvent. The liquid precursor preferably comprises a second organic precursor compound containing a second metal from the same group. Also, the liquid precursor preferably comprises an organic dopant precursor compound containing a metal selected from the group including niobium, tantalum, bismuth, cerium, yttrium, titanium, zirconium, hafnium, silicon, aluminum, zinc and magnesium. Liquid precursors containing a plurality of metals have a longer shelf life. The addition of an organic dopant precursor compound containing a metal, such as niobium, tantalum or bismuth, to the liquid precursor enhances control of the conductivity of the resulting transparent conductor.

Abstract: A liquid precursor for forming a transparent metal oxide thin film comprises a first organic precursor compound. In one embodiment, the liquid precursor is for making a conductive thin film. In this embodiment, the liquid precursor contains a first metal from the group including tin, antimony, and indium dissolved in an organic solvent. The liquid precursor preferably comprises a second organic precursor compound containing a second metal from the same group. Also, the liquid precursor preferably comprises an organic dopant precursor compound containing a metal selected from the group including niobium, tantalum, bismuth, cerium, yttrium, titanium, zirconium, hafnium, silicon, aluminum, zinc and magnesium. Liquid precursors containing a plurality of metals have a longer shelf life. The addition of an organic dopant precursor compound containing a metal, such as niobium, tantalum or bismuth, to the liquid precursor enhances control of the conductivity of the resulting transparent conductor.

Abstract: Tin polyaalkanecarboxylates having the formula [(R1pR2qSn)rOs]t wherein R1 represents C1-C6 alkyl, branched or straight, substituted or not by one or more hydroxyl groups or halogen atoms, or a phenyl group, substituted or not by one or more hydroxyl groups or halogen atoms, R2 is carboxylic residue selected from (I), (II), (III) or (IV); and p, q, r, s and t have the following meanings: P=3, q=1, r=1, s=) and t=1, p=2, q=2, r=1, s=0, and t=1, p=2, q=1, r=2, s=1 and t=2, have anti-tumor activity.

Abstract: A process for making a product containing tin (II) carboxylates of the formula (RCOO)2−n(OOCR′)n, where each R, which may be the same or different, is hydrogen or a C1-C40 hydrocarbyl group, each R′, which may be the same or different, is a C1-C40 hydrocarbyl group, and n is 0, 1, or 2 the process comprising: (a) forming a reaction mixture by combining elemental tin, a promoter, and one or more carboxylate-containing compounds of the formula R(CO)X, where R is hydrogen or a C1-C40 hydrocarbyl group and X is a hydroxyl group, a halogen atom, or O(CO)R′, where R′ is a C1-C40 hydrocarbyl group; (b) heating the reaction mixture to form heated reaction mixture; (c) oxidizing the heated reaction mixture using an oxygen-containing gas to form an oxidized reaction mixture containing tin (II) carboxylates as well as tin (IV) carboxylates; and (d) reducing the oxidized reaction mixture with elemental tin to convert at least a portion of the tin (IV) carboxylates to tin (II) carboxylate

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: Compounds which can chelate paramagnetic bi- and trivalent metal ions, their chelates with said metal ions and their use as contrast agents in magnetic resonance imaging (MRI), the compounds having formula (I) ##STR1## wherein R is a --(CH.sub.2).sub.m --O--R.sub.2 group or hydrogen,R.sub.2 is a (C.sub.6 -C.sub.10) aryl, or an alkyl(C.sub.1 -C.sub.5)-aryl(C.sub.6 -C.sub.10) group, substituted or not by a group L corresponding to a OH group or a OR.sub.3 group, wherein R.sub.3 is a linear or branched (C.sub.1 -C.sub.5) alkyl group; or L is NH.sub.2, halogen, COOH or CONR.sub.4 R.sub.5 wherein R.sub.4 and R.sub.5 are independently hydrogen, or a linear or branched (C.sub.1 -C.sub.5) alkyl which can be substituted by 1-6 hydroxy groups and/or 1-6 alkoxy groups,R.sub.1 can have the same meanings as R, independently from it, except for hydrogen,Z is independently OH or OR.sub.6, or NR.sub.4 R.sub.5 wherein R.sub.4 and R.sub.5 are as previously defined, and R.sub.6 is a (C.sub.1 -C.sub.

Abstract: The invention provides, as contrast signal generators in MR imaging of the digestive tract, paramagnetic metal chelates of novel acrylic compounds of formula C(R.sup.1 R.sup.2).dbd.CR.sup.3 --CO--Z--A (1) and/or C(R.sup.1 R.sup.2).dbd.CR.sup.3 --O--Z--A--Z--CO--CR.sup.3 .dbd.C(R.sup.1 R.sup.2) (2) in monomer, oligomer, homopolymer and copolymer forms, in which the R.sup.1, R.sup.2 and R.sup.3 represent H or saturated or unsaturated C.sub.1-10 aliphatic radicals optionally substituted by one or more OH groups; Z is a covalent bond or a linker spacer and A is a moiety capable of fixing a paramagnetic metal by chelation. Compounds of type (1) useful in the present invention are, for instance the polyalkylene-aminopolycaboxylic acids such as NTA, EDTA, DTPA, DOTA and like structures, possibly involving additional substituents; an example is the compound BOPTA which is a DTPA derivative carrying a benzyloxypropyl group.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: Novel metal acid salt complexes are provided comprising (1) a metal selected from Group IV and Group V metals and (2) a polyether acid, along with a process for making the salt complexes. The process comprises: (a) preparing a polyether acid anhydride from the corresponding polyether acid; and (b) combining a metal alkoxide containing the Group IV or Group V metal with the polyether acid anhydride to form the metal acid salt complex. The resulting Group IV and Group V metal acid salt complexes enable the production of improved thin film, thick film, and bulk ceramic metal oxides and mixed metal oxides for a number of applications, including ferroelectric, electrooptic, paraelectric, and piezoelectric devices, using liquid soluble precursors which are soluble in far less toxic solvents than in the prior art. The soluble ceramic precursors may also be used as reactive binders and shape-forming aids in conventional ceramic processing.

Abstract: The invention relates to a process for the production of metal-complex carboxylic acid amides, characterized in that a metal-complex carboxylic acid mixture that consists of the metal-complex carboxylic acid and at least one solubilizing substance in dimethyl sulfoxide (DMSO) is pretreated with a dehydrating reagent, optionally with the addition of a coupling adjuvant, and is then reacted with an amine of general formula IA(NH.sub.2).sub.n (I),in whichA stands for the radical of a natural or synthetic amine, andn stands for numbers 1 to 100.

Abstract: Disclosed are linear and cross-linked polymers suitable for use as a contrast agent for magnetic resonance imaging containing units comprising the residue of a poly(amine) moiety linked to a chelating agent and to one or more pendant (poly)alkylene oxides.

Abstract: This invention provides a method for synthesizing pure carboxyethyl germanium sesquioxide that does not include any toxic impurities, such as germanium dioxide or metallic germanium. Neither of these toxic compounds is used as a starting material. The method involves steps which ensure the full reaction of germanium tetrachloride in order to ensure that none is available to form germanium dioxide and steps which ensure the removal of any germanium dioxide.

Abstract: There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a dendritic polyamine backbone molecule, e.g. a starburst dendrimer. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.

Abstract: The invention relates to new, multiply substituted diethylenetriaminepentaacetic acid derivatives, their complexes and complex salts, that contain an element of atomic numbers 20-32, 39-51 or 57-83, pharmaceutical agents that contain these compounds, their use as contrast media and antidotes, and process for the production of pharmaceutical agents.

Abstract: The present invention relates to water-soluble, lipophilic contrast-enhancing agents, pharmaceutical compositions thereof and methods for diagnostic analysis, particularly NMR or MRI analysis using these contrast-enhancing agents. The water-soluble, lipophilic contrast-enhancing agents are chelates of a paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with completing acids which contain at least one short-chain fatty acyl moiety having from about 0 to about 6 carbon atoms in its structure.

Abstract: A contrast enhancing agent for magnetic resonance images having a chelating agent, which can be bound to metals having at least one unpaired electron. Examples of such chelating agents include 3,6,9-tris(carboxymethyl)-1, 11-bis(dimethylamine)-3,6,9-triazaundecane; 3,6,9-tris(carboxymethyl)-1, 11-bis(diethanolamino) 3,6,9-triazaundecane; 3,6,9-tris(carboxymethyl)-1, 11-bis(tris(hydroymethyl) aminomethane)-3,6,9-triazaundecane; 3,6-bis(carboxymethyl-1,8-bis(N-carboxymethylglucosamino)-3,6-diazoctane; DTPA-bis(galactosamide), DTPA-Bis(glucosamide), DTPA-Bis(pyridoxamide), and poly-(DTPA-ethylenediamide).

Abstract: Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue--(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.l --(O).sub.r --R,whereinm and n means the numbers 0-20,k, l, q and r means the numbers 0 and 1, andR means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning a hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group,with the proviso that at least two substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each means the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.

Abstract: Novel complexes of paramagnetic ions and compounds bearing long acyl chains have been synthesized as magnetic resonance imaging contrast agents. These novel liposoluble contrast agents may be administered alone, or with lipids, suspending agents or other additives. The lipids may be in the form of liposomes, micelles or lipid emulsions. The contrast agents of the invention have particular use in magnetic resonance imaging of the liver, blood pool and reticuloendothelial system.

Abstract: An amphipathic polychelating compound including a hydrophilic polymeric moiety having a main backbone and a plurality of reactive side groups, a lipid-soluble anchor linked to the N terminal of the polymeric moiety, and a plurality of chelating agents linked to the side groups of the polymeric moiety. The polychelating compounds are bound to liposomes or micelles for use as diagnostic and therapeutic agents.

Abstract: The invention relates to new diethylenetriaminepentaacetic acid derivatives, their complexes and complex salts, that contain an element of atomic numbers 20-32, 39-51 or 57-83, pharmaceutical agents that contain these compounds and their use as contrast media and antidotes.

Abstract: The invention relates to diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing gadolinium, dysprosium, iron or manganese, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.

Abstract: A synthetic method for generating pure carboxyethyl germanium sesquioxide in the absence of toxic impurities. In the method germanium dioxide and metallic germanium are not used as starting materials. The method involves steps which ensure (a) absence of any residual germanium tetrachloride to ensure none is available to form germanium dioxide, (b) removal of any germanium dioxide, (c) removal of any germanium tetrachloride later produced from any germanium dioxide and (d) final removal of any germanium dioxide. In an alternative method, intermediate TPA is prepared by direct precipitation from a concentrated solution with a halogenated solvent preferably dichloromethane when poured into a non-polar alkyl solvent preferably hexane at ambient temperature and then converted to carboxyethyl germanium sesquioxide.

Abstract: 1. Compounds of general Formula I ##STR1## wherein n and m in each case mean the numbers 0, 1, 2, 3 and 4,X stands for a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,R.sup.1 and R.sup.2, being different, mean in each case a hydrogen atom or a straight-chain, branched, saturated or unsaturated C.sub.0 -C.sub.20 -alkylene group, this alkylene group exhibiting at the end either a second molecule of general Formula I.sub.A or I.sub.

Abstract: Polymers comprising a ligand containing a carboxylic acid group, optionally at least one ion of an element of the atomic numbers 21-29, 42, 44 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides are valuable complexing agents and complexes for diagnosis.

Abstract: Metal complexes containing a metal of atomic numbers 39-42, 44-51 or 56-83 and a complexing agent can be used for the production of contrast media for use in the contrast-enhanced computer tomography of the liver and the biliary tracts.

Abstract: Emulsions of paramagnetic contrast agents, and processes of making and using them are disclosed. The emulsions contain water, a dispersed oil phase and a complex of a paramagnetic metal ion and an organic chelator having a C.sub.10 -C.sub.30 unsaturated aliphatic group. The emulsions are very stable and therapeutically acceptable for intravenous administration to enhance MRI.

Abstract: The invention relates to novel aromatic fluorine-containing organotin compounds of the formula {(F.sub.5 C.sub.6 RCO.sub.2 SnBu.sub.2).sub.2 O}.sub.2 and {(F.sub.5 C.sub.6 RCO.sub.2).sub.2 SnBu.sub.2 } wherein R is CH.sub.2, CH.dbd.CH or a single bond between the phenyl ring and the CO.sub.2 group, and Bu is a butyl group; as well as to anti-tumour compositions containing as an active ingredient one or more of these compounds.

Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.

Abstract: A synthetic method for generating pure carboxyethyl germanium sesquioxide in the absence of toxic impurities. In the method germanium dioxide and metallic germanium are not used as starting materials. The method involves steps which ensure (a) full reaction of germanium tetrachloride to ensure none is available to form germanium dioxide, (b) removal of any germanium dioxide, (c) removal of any germanium tetrachloride later produced from any germanium dioxide and (d) final removal of any germanium dioxide.